Nanoparticle-mediated RNA interference of angiotensinogen decreases blood pressure and improves myocardial remodeling in spontaneously hypertensive rats

Yuan,Li‑Fen; Sheng,Jing; Lu,Ping; Wang,Yu‑Qiang; Jin,Tuo; Du,Qin

doi:10.3892/mmr.2015.3909

Nanoparticle-mediated RNA interference of angiotensinogen decreases blood pressure and improves myocardial remodeling in spontaneously hypertensive rats

Authors:
- Li‑Fen Yuan
- Jing Sheng
- Ping Lu
- Yu‑Qiang Wang
- Tuo Jin
- Qin Du
View Affiliations

Affiliations: Department of Geriatrics, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, P.R. China
Published online on: June 11, 2015 https://doi.org/10.3892/mmr.2015.3909
Pages: 4657-4663

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Angiotensinogen (AGT) has been shown to have a role in cardiac hypertrophy, while depletion of the AGT gene in spontaneously hypertensive rats (SHR) has not been investigated. The present study investigated the effect of AGT knockdown on cardiac hypertrophy in SHR. For this, small hairpin (sh)RNAs were intravenously injected into SHRs, using a nanoparticle‑mediated transfection system. The experimental rats were divided into the following groups: a) Blank control with water treatment only, b) negative control with biscarbamate‑crosslinked Gal‑polyethylene glycol polyethylenimine nanoparticles (GPE)/negative shRNA, c) AGT‑RNA interference (RNAi) group with GPE/AGT‑shRNA, and 4) normotensive control using Wistar‑Kyoto rats (WKY) with water treatment. Three and five days following the first injection, the levels of hepatic AGT mRNA and AGT protein as well as plasma levels of AGT were markedly decreased in the AGT‑RNAi group (P<0.05). Furthermore, a significant decrease in systolic blood pressure (SBP), left ventricular weight to body weight ratio and heart weight to body weight ratio were observed in the AGT‑RNAi group compared with those in the control groups. The depletion of AGT in SHR led to a reduction in SBP by 30±4 mmHg, which was retained for >10 days. Cardiac hypertrophy was also signiﬁcantly improved in AGT‑knockdown rats. In conclusion, the present study showed that AGT‑silencing had a significant inhibitory effect on hypertension and hypertensive‑induced cardiac hypertrophy in SHRs.

View Figures

View References

1	Wang Z, Hao G, Zhang L, Chen Z, Wang X, Guo M, Tian Y, Shao L and Zhu M: Central systolic blood pressure is associated with ethnicity and cardiovascular disease risk factors in Chinese middle-aged population. Eur J Prev Cardiol. Mar 27–2015.Epub ahead of print. View Article : Google Scholar
2	Cano-Gutierrez C, Reyes-Ortiz CA, Samper-Ternent R, Gélvez-Rueda JS and Borda MG: Prevalence and factors associated to hypertension among older adults in Bogotá, Colombia. J Aging Health. Mar 24–2015.Epub ahead of print. View Article : Google Scholar
3	Mahn JJ, Dubey E, Brody A, Welch R, Zalenski R, Flack JM, Ference B and Levy PD: Test characteristics of electrocardiography for detection of left ventricular hypertrophy in asymptomatic emergency department patients with hypertension. Acad Emerg Med. 21:996–1002. 2014. View Article : Google Scholar : PubMed/NCBI
4	Luft FC: Present status of genetic mechanisms in hypertension. Med Clin North Am. 88:1–18. 2004. View Article : Google Scholar : PubMed/NCBI
5	Kern G, Mair SM, Noppert SJ, Jennings P, Schramek H, Rudnicki M, Mueller GA, Mayer G and Koppelstaetter C: Tacrolimus increases Nox4 expression in human renal fibroblasts and induces fibrosis-related genes by aberrant TGF-beta receptor signalling. PLoS One. 9:e963772014. View Article : Google Scholar : PubMed/NCBI
6	Pandey VG, Jain S, Rana A, Puri N, Arudra SK, Mopidevi B, Kaw M, Nasjletti A and Kumar A: Dexamethasone promotes hypertension by allele-specific regulation of the human angioten-sinogen gene. J Biol Chem. 290:5749–5758. 2015. View Article : Google Scholar : PubMed/NCBI
7	Qi Y, Zhang K, Wu Y, Xu Z, Yong QC, Kumar R, Baker KM, Zhu Q, Chen S and Guo S: Novel mechanism of blood pressure regulation by forkhead box class O1-mediated transcriptional control of hepatic angiotensinogen. Hypertension. 64:1131–1140. 2014. View Article : Google Scholar : PubMed/NCBI
8	Alves M, Souza e Silva NA, Salis LH, Pereira Bde B, Godoy PH, Nascimento EM and Oliveira JM: Survival and predictive factors of lethality in hemodialysis: D/I polymorphism of the angio-tensin I-converting enzyme and of the angiotensinogen M235T genes. Arq Bras Cardiol. 103:209–219. 2014.PubMed/NCBI
9	Zhu X, Chang YP, Yan D, Weder A, Cooper R, Luke A, Kan D and Chakravarti A: Associations between hypertension and genes in the reninangiotensin system. Hypertension. 41:1027–1034. 2003. View Article : Google Scholar : PubMed/NCBI
10	Kolder IC, Michels M, Christiaans I, Ten Cate FJ, Majoor-Krakauer D, Danser AH, Lekanne Deprez RH, Tanck M, Wilde AA, Bezzina CR, et al: The role of renin-angiotensin-aldo-sterone system polymorphisms in phenotypic expression of MYBPC3-related hypertrophic cardiomyopathy. Eur J Hum Genet. 20:1071–1077. 2012. View Article : Google Scholar : PubMed/NCBI
11	Xu P, Wang Y, Sterner-Kock A, Bader M, Schultheiss HP and Walther T: Excessive hypertension and end-organ damage in a transgenic mouse line carrying the rat angiotensinogen gene. J Cardiovasc Pharmacol. 53:38–43. 2009. View Article : Google Scholar : PubMed/NCBI
12	Makino N, Sugano M, Ohtsuka S and Sawada S: Intravenous injection with antisense oligodeoxynucleotides against angioten-sinogen decreases blood pressure in spontaneously hypertensive rats. Hypertension. 31:1166–1170. 1998. View Article : Google Scholar : PubMed/NCBI
13	Caulfield M, Lavender P, Farrall M, Munroe P, Lawson M, Turner P and Clark AJ: Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med. 330:1629–1633. 1994. View Article : Google Scholar : PubMed/NCBI
14	Feng PF, Liu Y and Qin NP: Effect of sanwu hypotensive decoction on blood pressure and lymphokine activated killer cell in patient of primary hypertension and spontaneously hypotensive rats. Zhongguo Zhong Xi Yi Jie He Za Zhi. 21:342–345. 2001.
15	Pinto YM, Paul M and Ganten D: Lessons from rat models of hypertension: From Goldblatt to genetic engineering. Cardiovasc Res. 39:77–88. 1998. View Article : Google Scholar : PubMed/NCBI
16	Wright JW, Mizutani S, Murray CE, Amir HZ and Harding JW: Aminopeptidase-induced elevations and reductions in blood pressure in the spontaneously hypertensive rat. J Hypertens. 8:969–974. 1990. View Article : Google Scholar : PubMed/NCBI
17	Lemmer B, Mattes A, Böhm M and Ganten D: Circadian blood pressure variation in transgenic hypertensive rats. Hypertension. 22:97–101. 1993. View Article : Google Scholar : PubMed/NCBI
18	Lee RM: Structural alterations of blood vessels in hypertensive rats. Can J Physiol Pharmacol. 65:1528–1535. 1987. View Article : Google Scholar : PubMed/NCBI
19	Rippe B, Lundin S and Folkow B: Plasma volume, blood volume and transcapillary escape rate (TER) of albumin in young spontaneously hypertensive rats (SHR) as compared with normotensive controls (NCR). Clin Exp Hypertens. 1:39–50. 1978. View Article : Google Scholar : PubMed/NCBI
20	Andresen MC, Krauhs JM and Brown AM: Relationship of aortic wall and baroreceptor properties during development in normotensive and spontaneously hypertensive rats. Circ Res. 43:728–738. 1978. View Article : Google Scholar : PubMed/NCBI
21	Xi-Ye Fang: Medical Experimental Zoology. 1st edition. People's Medical Publishing House; Beijing: pp. p1211995
22	Wakui H, Tamura K, Masuda S, Tsurumi-Ikeya Y, Fujita M, Maeda A, Ohsawa M, Azushima K, Uneda K, Matsuda M, et al: Enhanced angiotensin receptor-associated protein in renal tubule suppresses angiotensin-dependent hypertension. Hypertension. 61:1203–1210. 2013. View Article : Google Scholar : PubMed/NCBI
23	Nabeshima Y, Tazuma S, Kanno K, Hyogo H and Chayama K: Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol. 50:1226–1235. 2009. View Article : Google Scholar : PubMed/NCBI
24	Yue H, Li W, Desnoyer R and Karnik SS: Role of nuclear unphos-phorylated STAT3 in angiotensin II type 1 receptor-induced cardiac hypertrophy. Cardiovasc Res. 85:90–99. 2010. View Article : Google Scholar
25	Chen X, Qiu Z, Yang S, Ding D, Chen F, Zhou Y, Wang M, Lin J, Yu X, Zhou Z, et al: Effectiveness and safety of a therapeutic vaccine against angiotensin II receptor type 1 in hypertensive animals. Hypertension. 61:408–416. 2013. View Article : Google Scholar
26	He J, Bian Y, Gao F, Li M, Qiu L, Wu W, Zhou H, Liu G and Xiao C: RNA interference targeting the ACE gene reduced blood pressure and improved myocardial remodelling in SHRs. Clin Sci (Lond). 116:249–255. 2009. View Article : Google Scholar
27	Lu P, Yuan L, Wang Y, Du Q and Sheng J: Effect of GPE-AGT nanoparticle shRNA transfection system mediated RNAi on early atherosclerotic lesion. Int J Clin Exp Pathol. 5:698–706. 2012.PubMed/NCBI
28	Gong H, Liu CM, Liu DP and Liang CC: The role of small RNAs in human diseases: Potential troublemaker and therapeutic tools. Med Res Rev. 25:361–381. 2005. View Article : Google Scholar : PubMed/NCBI
29	Park TG, Jeong JH and Kim SW: Current status of polymeric gene delivery systems. Adv Drug Deliv Rev. 58:467–486. 2006. View Article : Google Scholar : PubMed/NCBI
30	Srinivas R, Samanta S and Chaudhuri A: Cationic amphiphiles: Promising carriers of genetic materials in gene therapy. Chem Soc Rev. 38:3326–3338. 2009. View Article : Google Scholar
31	Mintzer MA and Simanek EE: Nonviral vectors for gene delivery. Chem Rev. 109:259–302. 2009. View Article : Google Scholar
32	Yu H and Wagner E: Bioresponsive polymers for nonviral gene delivery. Curr Opin Mol Ther. 11:165–178. 2009.PubMed/NCBI
33	Wang YQ, Su J, Wu F, Lu P, Yuan LF, Yuan WE, Sheng J and Jin T: Biscarbamate cross-linked polyethylenimine derivative with low molecular weight, low cytotoxicity, and high efficiency for gene delivery. Int J Nanomedicine. 7:693–704. 2012.PubMed/NCBI
34	Lu P, Yuan L, Wang Y, Du Q and Sheng J: Effect of GPE-AGT nanoparticle shRNA transfection system mediated RNAi on early atherosclerotic lesion. Int J Clin Exp Pathol. 5:698–706. 2012.PubMed/NCBI
35	Wang Y, Su J, Cai W, Lu P, Yuan L, Jin T, Chen S and Sheng J: Hepatocyte-targeting gene transfer mediated by galactosylated poly(ethylene glycol)-graft-polyethylenimine derivative. Drug Des Devel Ther. 7:211–221. 2013. View Article : Google Scholar : PubMed/NCBI
36	Zhang X, Gao Y, Dong J, Wang S, Yao B, Zhang J, Hu S, Xu X, Zuo H, Wang L, et al: The compound Chinese medicine 'Kang Fu Ling' protects against high power microwave-induced myocardial injury. PLoS One. 9:e1015322014. View Article : Google Scholar
37	Silvani A, Bastianini S, Berteotti C, Cenacchi G, Leone O, Lo Martire V, Papa V and Zoccoli G: Sleep and cardiovascular phenotype in middle-aged hypocretin-deficient narcoleptic mice. J Sleep Res. 23:98–106. 2014. View Article : Google Scholar
38	Li D, Lv J, Liu F, Liu P, Yang X, Feng Y, Chen G and Hao M: Hypertension burden and control in mainland China: Analysis of nationwide data 2003–2012. Int J Cardiol. 184:637–644. 2015. View Article : Google Scholar : PubMed/NCBI
39	Khandelia P, Yap K and Makeyev EV: Streamlined platform for short hairpin RNA interference and transgenesis in cultured mammalian cells. Proc Natl Acad Sci USA. 108:12799–12804. 2011. View Article : Google Scholar : PubMed/NCBI
40	Maillard PV, Ciaudo C, Marchais A, Li Y, Jay F, Ding SW and Voinnet O: Antiviral RNA interference in mammalian cells. Science. 342:235–238. 2013. View Article : Google Scholar : PubMed/NCBI
41	Li Y, Lu J, Han Y, Fan X and Ding SW: RNA interference functions as an antiviral immunity mechanism in mammals. Science. 342:231–234. 2013. View Article : Google Scholar : PubMed/NCBI
42	Lebedev TD, Spirin PV and Prassolov VS: Transfer and expression of small interfering RNAs in mammalian cells using lentiviral vectors. Acta Naturae. 5:7–18. 2013.PubMed/NCBI
43	Hannon GJ: RNA interference. Nature. 418:244–251. 2002. View Article : Google Scholar : PubMed/NCBI
44	Pare JM, LaPointe P and Hobman TC: Hsp90 cochaperones p23 and FKBP4 physically interact with hAgo2 and activate RNA interference-mediated silencing in mammalian cells. Mol Biol Cell. 24:2303–2310. 2013. View Article : Google Scholar : PubMed/NCBI
45	Paddison PJ: RNA interference in mammalian cell systems. Curr Top Microbiol Immunol. 320:1–19. 2008.PubMed/NCBI
46	Dalmay T: MicroRNAs and cancer. J Intern Med. 263:366–375. 2008. View Article : Google Scholar : PubMed/NCBI
47	Ohkumo T, Masutani C, Eki T and Hanaoka F: Use of RNAi in C. elegans. Methods Mol Biol. 442:129–137. 2008. View Article : Google Scholar : PubMed/NCBI
48	Huang DD: The potential of RNA interference-based therapies for viral infections. Curr HIV/AIDS Rep. 5:33–39. 2008. View Article : Google Scholar : PubMed/NCBI
49	Chen Y, Cheng G and Mahato RI: RNAi for treating hepatitis B viral infection. Pharm Res. 25:72–86. 2008. View Article : Google Scholar :
50	Volarevic M, Smolic R, Wu CH and Wu GY: Potential role of RNAi in the treatment of HCV infection. Expert Rev Anti Infect Ther. 5:823–831. 2007. View Article : Google Scholar : PubMed/NCBI
51	Singh SK: RNA interference and its therapeutic potential against HIV infection. Expert Opin Biol Ther. 8:449–461. 2008. View Article : Google Scholar : PubMed/NCBI
52	Ying SY and Lin SL: Current perspectives in intronic micro RNAs (miRNAs). J Biomed Sci. 13:5–15. 2006. View Article : Google Scholar
53	Chen D, Hazelwood L, Walker LL, Oldfield BJ, McKinley MJ and Allen AM: Changes in angiotensin type 1 receptor binding and angiotensin-induced pressor responses in the rostral ventrolateral medulla of angiotensinogen knockout mice. Am J Physiol Regul Integr Comp Physiol. 298:R411–R418. 2010. View Article : Google Scholar